@prefix : <http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#> .
@prefix mp: <http://purl.org/mp/> .
@prefix oa: <http://www.w3.org/ns/oa#> .
@prefix opv: <http://inab.certh.gr/OpenPVSignal> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix openpvsignal: <http://purl.org/OpenPVSignal/OpenPVSignal.owl> .
@base <http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl> .

<http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl> rdf:type owl:Ontology ;
                                                                           owl:imports <http://purl.org/OpenPVSignal/OpenPVSignal.owl> ,
                                                                                       mp: ;
                                                                           rdfs:comment "OpenPVSignal ontology describes a model able to present pharmacovigilance signal information, originally contained in free-text reports."^^rdfs:Literal ;
                                                                           rdfs:isDefinedBy "https://apps.who.int/iris/handle/10665/272398"^^xsd:anyURI ;
                                                                           rdfs:label "Quetiapine and valproic acid interactions: signal strengthening"^^rdfs:Literal ;
                                                                           owl:versionInfo "draft-v0.95-20210319"@en .

#################################################################
#    Object Properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element
<http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> rdf:type owl:ObjectProperty .


###  http://purl.org/mp/publishedBy
mp:publishedBy rdf:type owl:ObjectProperty .


###  http://purl.org/mp/references
mp:references rdf:type owl:ObjectProperty .


#################################################################
#    Data properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_affiliation
<http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_affiliation> rdfs:subPropertyOf mp:editedOn .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#refers_to_rechallenge_process
:refers_to_rechallenge_process rdf:type owl:DatatypeProperty .


###  http://www.w3.org/2006/time#nominalPosition
<http://www.w3.org/2006/time#nominalPosition> rdf:type owl:DatatypeProperty .


###  http://www.w3.org/2006/time#numericPosition
<http://www.w3.org/2006/time#numericPosition> rdf:type owl:DatatypeProperty .


#################################################################
#    Classes
#################################################################

###  http://www.w3.org/2006/time#DurationDescription
<http://www.w3.org/2006/time#DurationDescription> rdf:type owl:Class .


#################################################################
#    Individuals
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#AstraZeneca_sponsored_study
:AstraZeneca_sponsored_study rdf:type owl:NamedIndividual ,
                                      <http://purl.obolibrary.org/obo/OAE_0001125> ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ,
                                                                                            :valproicAcid ;
                             mp:references :Ref.10 ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The US Food and Drug Administration label cites an Astra Zeneca sponsored study from 2007, which found that adding 1000 mg/day of divalproex, a valproic acid formulation, to 300 mg/ day of quetiapine produced a 17% mean increase in maximum plasma quetiapine concentration at steady state. At the same daily doses, valproic acid maximum plasma concentration at steady state was found to be reduced by 10-12%.10" ;
                             rdfs:label "AstraZeneca sponsored study" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#BattenDisease
:BattenDisease rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E75.4" ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10052082 ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Batten's disease" ;
               rdfs:label "batten disease" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#BipolarDisorder
:BipolarDisorder rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "F31" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10057667 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "bipolar disorder" ;
                 rdfs:label "bipolar disorder" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#CaseReportInfo1
:CaseReportInfo1 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "In  case 1, the reporter concluded that the patient  was predisposed to valproic acid  hepatotoxicity on the basis of repeated  positive rechallenges, and that quetiapine was  responsible for the CPK increase. After  withdrawal of valproate, the patient recovered  from hepatic complications, after quetiapine  dechallenge his CPK went back to normal." ,
                                                                             """Literature reference: Erdogan et al. VA levels: 50 mg/l, thyroid function normal.
AST, ALT, LDH elevation linked to VA, while CPK and CPK-MB increase to Q.
History of hepatic enzyme increases while on VA and CPK increase on Q. VA
withdrawn first, with lowering of hepatic enzymes. Followed by increase in CPK
after Q dose was raised to 400 mg/day. Q then discontinued and CPK values back to normal.""" ;
                 rdfs:label "Case report info 1" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#CaseReportInfo10
:CaseReportInfo10 rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Cases which did  not co-report any of the above discussed  conditions are 9 and 10, both describing a  decrease in consciousness. Both could be  quetiapine dose-related: the first reports a prescribed overdose, and the second an unintentional four-fold overdose due to lack of patient adherence." ,
                                                                              """Hospitalized due to fever and suspected
pneumonia, treated with levofloxacin.
Antipsychotic regimen had not been taken by
patient and was started during hospital stay.""" ;
                  rdfs:label "Case report info 10" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#CaseReportInfo11
:CaseReportInfo11 rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "In another patient (case 11), depressed consciousness co-occurred with gait disturbances and around the same time of a quetiapine dose increase. The reported off-label indication was depression, and the incremental dosing occurred according to the label. " ,
                                                                              """The overdose was not intentional but reported
by the patient as she considered her physician
to be overdosing her.""" ;
                  rdfs:label "Case report info 11" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#CaseReportInfo12
:CaseReportInfo12 rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Case 12 reports pseudoparkinsonism induced by increased plasma levels of quetiapine." ,
                                                                              """Literature reference: De Dios et al. Cortical-subcortical atrophy. VA: 78 mg/l after
events.""" ;
                  rdfs:label "Case report info 12" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#CaseReportInfo13
:CaseReportInfo13 rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """History: benign prostatic hyperplasia, lacunar
infarction, nervous system disorder NOS,
cerebral degeneration, emergency care,
hospitalization, chronic kidney disease.
Q was added on VA and lithium.
VA dose brought up from 900 mg per day to
1600 mg per day on the day Q was started.
Q: 283 mcg/l (reference:
70-170 mcg/l); VA within therapeutic levels;
aripiprazole below therapeutic levels.""" ,
                                                                              "Similarly, case 13 lists parkinsonism and depressed consciousness, attributed to a pharmacokinetic interaction leading to increased quetiapine plasma levels and a recovery after dose reduction." ;
                  rdfs:label "Case report info 13" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#CaseReportInfo17
:CaseReportInfo17 rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                  mp:references :Ref.17 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Alternatively, valproic acid  encephalopathy can also reasonably explain  decreased consciousness and coma. Valproic  acid metabolites can inhibit the urea cycle and  cause hyperammonemia, as in case 17. 17" ,
                                                                              """Literature reference: Erling et al.
Hyperammonemic coma due to VA. VA:
756 mcmol/l (no reference provided but
above therapeutic).""" ;
                  rdfs:label "Case report info 17" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#CaseReportInfo18
:CaseReportInfo18 rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Literature reference: Wu et al.
Coma/depressed consciousness due to
hyperglycaemia (high- sugar dieting habits).
Patient without history of diabetes.""" ,
                                                                              "Wu  et al. (case 18) suggest that the patient’s  hyperglycaemic coma was promoted by high  dose quetiapine and possibly complicated by  valproic acid co-administration, but worsened  by high sugar consumption." ;
                  rdfs:label "Case report info 18" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#CaseReportInfo19
:CaseReportInfo19 rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """VA introduced after 11 days of Q use. Q can
increase plasma concentration of lithium.""" ;
                  rdfs:label "Case report info 19" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#CaseReportInfo2
:CaseReportInfo2 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Literature reference: Reiche et al.
Suspected interaction between VA and
pipamperone as well as between VA and
Q. Q levels below therapeutic: 25 ng/ml
(reference 70-170 ng/ml), VA levels within
therapeutic range: 46 mcg/ml (reference 30-
100 mcg/ml).""" ,
                                                                             "Reiche et al. (case 2) suggest a blood CPK  increase caused by valproic acid resulting from  prolonged clearance due to interaction with  concomitant pipamperone. They do not,  however, exclude the possibility of a  pharmacodynamic interaction between valproic  acid and quetiapine, adding that quetiapine  was below therapeutic levels at admission to  hospital." ;
                 rdfs:label "Case report info 2" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#CaseReportInfo20
:CaseReportInfo20 rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Possible error in reporting VA dose (mg instead
of grams).""" ;
                  rdfs:label "Case report info 20" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#CaseReportInfo4
:CaseReportInfo4 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "In case 4, a quetiapine valproate pharmacokinetic interaction  was suspected to have induced rhabdomyolysis as  part of an abortive NMS form. The patient’s  symptoms began with neck stiffness, which  resembles a cervical dystonia literature case,  suspected to have been a pharmacokinetic  interaction between quetiapine and valproic  acid. 23 " ,
                                                                             """Literature reference: Jahn et al.
Suspect of abortive neuroleptic malignant
syndrome with fever (37.9 C), tremor in
extremities. VA 82.4 mg/l.""" ;
                 rdfs:label "Case report info 4" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#CaseReportInfo5
:CaseReportInfo5 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Cases 5 and 6 are confounded by  respiratory infection and NMS respectively." ;
                 rdfs:label "Case report info 5" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#CaseReportInfo6
:CaseReportInfo6 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Cases 5 and 6 are confounded by  respiratory infection and NMS respectively." ;
                 rdfs:label "Case report info 6" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#CaseReportInfo7
:CaseReportInfo7 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "In case 7, marked increases of  antipsychotic plasma levels due to  pharmacokinetic interaction could have  induced NMS." ,
                                                                             """Q above studied doses. Mental disorders
due to brain damage. Chronic obstructive
pulmonary disease, smoker, fever 38.1 C. Q
plasma concentration: 3498 nmol/l
(reference 183-442 nmol/l) 1 day after
withdrawal. C-reactive protein: 83 mg/l.
Pipamperone was taken for 9 days, in
overlap with Q/VA.""" ;
                 rdfs:label "Case report info 7" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#CaseReportInfo8
:CaseReportInfo8 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Acute cholecystitis. Developed reactions after
surgery, lithium- induced diabetes insipidus
pre-existing, hypernatraemia due to
decreased consciousness and subsequent
reduced liquids intake. Recent increase of Q.""" ,
                                                                             "In case 8, extrapyramidal symptoms and depressed level of consciousness are co-reported after quetiapine dose increase" ;
                 rdfs:label "Case report info 8" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#CaseReportInfo9
:CaseReportInfo9 rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Cases which did  not co-report any of the above discussed  conditions are 9 and 10, both describing a  decrease in consciousness. Both could be  quetiapine dose-related: the first reports a prescribed overdose, and the second an unintentional four-fold overdose due to lack of patient adherence." ,
                                                                             """Q above studied doses. Q at 191 ng/ml
(reference 70-170 ng/ ml). VA at 11.2
mcg/ml (reference 50-100 mcg/ml).
Reactions occurred at the day of peak Q
concentration. VA was introduced the same
day. Perazine cannot be excluded, but was
introduced five days before valproate""" ;
                 rdfs:label "Case report info 9" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Daniele_Sartori
:Daniele_Sartori rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Author> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_affiliation> "Upsalla Monitoring Centre" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_first_name> "Daniele" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_last_name> "Sartori" ;
                 rdfs:label "Daniele Sartori" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Depression
:Depression rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "F32" ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10012378 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "depression" ;
            rdfs:label "depression" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Discussion
:Discussion rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Discussion> ;
            mp:references :Ref.17 ,
                          :Ref.20 ,
                          :Ref.21 ,
                          :Ref.22 ,
                          :Ref.23 ,
                          :Ref.24 ,
                          :Ref.25 ,
                          :Ref.26 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Quetiapine and valproic acid are known to interact  as two central nervous system (CNS) depressant  agents. The interaction is not thought to be  linically significant and is regarded as “well  tolerated”, however, therapeutic drug monitoring  has been recommended. 20 By contrast, most of the  assessed cases (15/20) were reported as serious.  For rhabdomyolysis and increases in blood CPK, the  time to onset is consistent with a drug induced  effect, yet the reactions per se could be explained by concomitant diseases, co-reported terms or  co-administered medicines. The musculoskeletal subgroup contributes with  4 males and 1 female to the uneven sex ratio  in the case series (13 males and 7 females).  Fat-to-muscle ratio differences between sexes  can account for rhabdomyolysis. Other  alternative explanations include: potentially  undiagnosed glycolysis, glycogenolysis, and  pentose phosphate pathways enzymatic  polymorphism, mitochondrial toxicity and  calcium homeostasis dysregulation. 21 Additionally, rhabdomyolysis is part of the  neuroleptic malignant syndrome (NMS) clinical  presentation, which is known to be more  frequent in men. 22 In case 4, a quetiapinevalproate pharmacokinetic interaction  was suspected to have induced rhabdomyolysis as  part of an abortive NMS form. The patient’s  symptoms began with neck stiffness, which  resembles a cervical dystonia literature case,  suspected to have been a pharmacokinetic  interaction between quetiapine and valproic  acid. 23 Cases 5 and 6 are confounded by  respiratory infection and NMS respectively. In  case 1, the reporter concluded that the patient  was predisposed to valproic acid  hepatotoxicity on the basis of repeated  positive rechallenges, and that quetiapine was  responsible for the CPK increase. After  withdrawal of valproate, the patient recovered  from hepatic complications, after quetiapine  dechallenge his CPK went back to normal.  Reiche et al. (case 2) suggest a blood CPK  increase caused by valproic acid resulting from  prolonged clearance due to interaction with  concomitant pipamperone. They do not,  however, exclude the possibility of a  pharmacodynamic interaction between valproic  acid and quetiapine, adding that quetiapine  was below therapeutic levels at admission to  hospital. Accounting for potential confounders in the  neuropsychiatric group, consciousness  fluctuations and coma are also symptoms of  NMS. In case 7, marked increases of  antipsychotic plasma levels due to  pharmacokinetic interaction could have  induced NMS. Alternatively, valproic acid  encephalopathy can also reasonably explain  decreased consciousness and coma. Valproic  acid metabolites can inhibit the urea cycle and  cause hyperammonemia, as in case 17. 17 Wu  et al. (case 18) suggest that the patient’s  hyperglycaemic coma was promoted by high  dose quetiapine and possibly complicated by  valproic acid co-administration, but worsened  by high sugar consumption. Cases which did  not co-report any of the above discussed  conditions are 9 and 10, both describing a  decrease in consciousness. Both could be  quetiapine dose-related: the first reports a 

prescribed overdose, and the second an unintentional four-fold overdose due to lack of patient adherence. Some cases list extrapyramidal symptoms, a known side effect of antipsychotics. Case 12 reports pseudoparkinsonism induced by increased plasma levels of quetiapine. Similarly, case 13 lists parkinsonism and depressed consciousness, attributed to a pharmacokinetic interaction leading to increased quetiapine plasma levels and a recovery after dose reduction. In another patient (case 11), depressed consciousness co-occurred with gait disturbances and around the same time of a quetiapine dose increase. The reported off-label indication was depression, and the incremental dosing occurred according to the label. In case 8, extrapyramidal symptoms and depressed level of consciousness are co-reported after quetiapine dose increase. Quetiapine overdose leads to CNS depression and increased plasma levels due to pharmacokinetic interactions can have the same effect. In addition to polytherapy-induced interactions, smoking, alcohol, and drug abuse are prevalent in patients affected by psychotic disorders.24Quetiapine pharmacokinetics do not seem to be altered by smoking. Nicotine however, is metabolized by CYP2A6, the same cytochrome which hydroxylates valproic acid.25,26These considerations are applicable to case 7, a smoker. Smoker status, alcohol or substance abuse could have been unreported in the rest of the case series.""" ;
            rdfs:label "Discussion" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#DosageForExtendedReleaseQForManicEpisodes
:DosageForExtendedReleaseQForManicEpisodes rdf:type owl:NamedIndividual ,
                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "For extended  release: 300 mg/day for the first two days,  with 400-800 mg/day by day three." ;
                                           rdfs:label "Dosage for extended release Q for manic episodes" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#DosageForImmediateReleaseQForManicEpisodes
:DosageForImmediateReleaseQForManicEpisodes rdf:type owl:NamedIndividual ,
                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Immediate release  quetiapine is initiated at 100 mg per day in  manic episodes and may be increased up to  800 mg/day over six days, with increments  no higher than 200 mg/day.  " ;
                                            rdfs:label "Dosage for immediate release Q for manic episodes" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#DosageForReportsWithMusculoskeletalReportedAdverseEventsPTs
:DosageForReportsWithMusculoskeletalReportedAdverseEventsPTs rdf:type owl:NamedIndividual ,
                                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The highest dose of Quetiapine  per patient ranged from 50-500 mg/day, while the  highest for valproic acid was 250-1500 mg/day" ;
                                                             rdfs:label "Dosage for reports with Musculoskeletal reported adverse events PTs" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#DosageForReportsWithNeuropsychiatricReportedAdverseEventsPTs
:DosageForReportsWithNeuropsychiatricReportedAdverseEventsPTs rdf:type owl:NamedIndividual ,
                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The highest dose of quetiapine per  patient ranged from 200-950 mg/day, while the  highest for valproic acid was 300-2500 mg/day.  " ;
                                                              rdfs:label "Dosage for reports with Neuropsychiatric reported adverse events PTs" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#DosageForVAInMania
:DosageForVAInMania rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Valproic  acid doses in mania are mostly documented  as monotherapy at 600-750 mg/day. The dose should be increased by 200 mg/day  every three days, up to a total of 2500  mg/day in uncontrolled mania. " ;
                    rdfs:label "Dosage for VA in mania" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Dosage_info
:Dosage_info rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ,
                                                                            :valproicAcid ;
             mp:references :Ref.8 ,
                           :Ref.9 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Recommended doses of quetiapine in adjunct 
to valproic acid, for both acute and 
maintenance bipolar disorder treatment, are 
400-800 mg per day. Immediate release 
quetiapine is initiated at 100 mg per day in 
manic episodes and may be increased up to 
800 mg/day over six days, with increments 
no higher than 200 mg/day. For extended 
release: 300 mg/day for the first two days, 
with 400-800 mg/day by day three. Valproic 
acid doses in mania are mostly documented 
as monotherapy at 600-750 mg/day. The 
dose should be increased by 200 mg/day 
every three days, up to a total of 2500 
mg/day in uncontrolled mania.8,9""" ;
             rdfs:label "Dosage info" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#EU_SmPC_for_quetiapine
:EU_SmPC_for_quetiapine rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Structured_Product_Labels_information> ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :coma ,
                                                                                                 :creatineKinaseMbIncreased ,
                                                                                                 :rhabdomyolysis ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ,
                                                                                       :valproicAcid ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Rhabdomyolysis, creatine phosphokinase (CPK) increase and coma (including hyperglycaemic coma) are on the EU SmPC for quetiapine" ,
                                                                                    "The European Union Summary of Product Characteristics (EU SmPC) for quetiapine mentions an increased risk of antipsychotic-induced side effects when valproic acid is co-administered, but adds that the combination of quetiapine and valproic acid was well tolerated." ;
                        rdfs:label "EU SmPC for quetiapine" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#EU_SmPC_for_valproic_acid
:EU_SmPC_for_valproic_acid rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Structured_Product_Labels_information> ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :conciousnessClouding ,
                                                                                                    :hyperammonemicComa ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "the valproic acid EU SmPC includes hyperammonemic coma and consciousness clouding" ;
                           rdfs:label "EU SmPC for valproic acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Literature_and_Labelling
:Literature_and_Labelling rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Literature_information> ;
                          mp:references :Ref.10 ,
                                        :Ref.11 ,
                                        :Ref.12 ,
                                        :Ref.13 ,
                                        :Ref.14 ,
                                        :Ref.15 ,
                                        :Ref.16 ,
                                        :Ref.17 ,
                                        :Ref.18 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The European Union Summary of Product  Characteristics (EU SmPC) for quetiapine  mentions an increased risk of antipsychotic-induced side effects when valproic acid is coadministered, but adds that the combination of  quetiapine and valproic acid was well tolerated.  The US Food and Drug Administration label cites an Astra Zeneca sponsored study from 2007, which found that adding 1000 mg/day of divalproex, a valproic acid formulation, to 300 mg/ day of quetiapine produced a 17% mean increase  in maximum plasma quetiapine concentration at  steady state. At the same daily doses, valproic acid maximum plasma concentration at steady state was found to be reduced by 10-12%. 10 Conversely, a smaller study showed an increase in up to 77% of plasma quetiapine concentrations, when given together with valproic acid. 11 Rhabdomyolysis, creatine phosphokinase (CPK) increase and coma (including hyperglycaemic  coma) are on the EU SmPC for quetiapine, while  the valproic acid EU SmPC includes  hyperammonemic coma and consciousness  clouding. Stockley’s Drug Interactions describe the evidence  on a pharmacokinetic interaction between  quetiapine and valproic acid as “limited”, adding  that the two do not appear to alter each other’s  exposure. Based on the evidence considered, dose  adjustments are not deemed necessary in  concurrent use. 12 The literature reveals several serious cases on  concurrent quetiapine and valproic acid use,  describing musculoskeletal and neuropsychiatric  suspected adverse reactions attributed to one of the  drugs or to interaction between the two. Six cases  presented here were published and reported to  VigiBase, the WHO global database of individual  case safety reports (ICSRs). A 26-year-old male, with a history of CPK increases under quetiapine, was reported to have CPK-raised  blood levels under quetiapine/valproic acid. After  the valproic treatment was stopped due to a  suspicion of hepatic toxicity and the quetiapine  dose was doubled, the patient complained of  myalgia accompanied by increased CPK. From this,  quetiapine was thought to have caused the  reaction. 13 An 85-year-old female treated for four  days with quetiapine and valproic acid was found to have CPK increase. The authors did not exclude the  possibility of an interaction with pipamperone, nor a pharmacodynamic one with subtherapeutic  quetiapine. 14 Rhabdomyolysis and increased CPK  were also described in a 37-year-old male who  complained of neck muscles stiffness and malaise.  The authors postulated a pharmacokinetic  interaction between valproic acid and quetiapine  had resulted in the inhibition of CYP3A4, one of  quetiapine’s main metabolic pathways. 15 A 66-year-old patient experienced depressed level  of consciousness and reversible parkinsonism due  to a suspected pharmacokinetic interaction  between quetiapine and valproic acid. The  symptoms appeared after the quetiapine dose had  recently been increased to the maximum daily  dose of 800 mg, but quetiapine plasma levels  were not measured. 16 A 19-year-old patient  affected by Batten disease (neuronal ceroid  lipofuscinosis – a rare genetic disorder), fell  into a hyperammonemic coma three weeks  after valproic acid treatment was added to  quetiapine 200 mg/day. The patient recovered  after valproic acid discontinuation, but the  authors did not suspect an interaction. 17 In  another case quetiapine was suspected of  having promoted a hyperosmolarhyperglycaemic coma in the presence of  valproic acid. 18 An increased exposure to  quetiapine due to valproic acid may have  occurred, but both drugs have the potential to  trigger this  condition." ;
                          rdfs:label "Literature and Labelling" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#OneDayIntervalBetweenAdministrations
:OneDayIntervalBetweenAdministrations rdf:type owl:NamedIndividual ,
                                               <http://www.w3.org/2006/time#DurationDescription> ;
                                      <http://www.w3.org/2006/time#nominalPosition> "days" ;
                                      <http://www.w3.org/2006/time#numericPosition> 1 ;
                                      rdfs:label "One day interval between administrations" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#OverallReportsInVigibaseForQAndVAco-reportedAsSuspectedOrInteracting
:OverallReportsInVigibaseForQAndVAco-reportedAsSuspectedOrInteracting rdf:type owl:NamedIndividual ,
                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ,
                                                                                                                                     :valproicAcid ;
                                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1522 ;
                                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                      rdfs:label "Overall reports in Vigibase for Q and VA co-reported as suspected or interacting" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient1
:Patient1 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 26 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 1" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient10
:Patient10 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 39 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 10" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient11
:Patient11 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 54 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 11" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient12
:Patient12 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 66 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 12" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient13
:Patient13 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 74 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 13" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient14
:Patient14 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 14" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient15
:Patient15 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 15" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient16
:Patient16 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 57 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 16" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient17
:Patient17 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 19 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 17" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient18
:Patient18 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 39 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 18" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient19
:Patient19 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 38 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 19" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient2
:Patient2 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 85 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
          rdfs:label "Patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient20
:Patient20 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 21 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 20" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient3
:Patient3 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 27 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient4
:Patient4 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 37 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 4" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient5
:Patient5 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 54 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 5" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient6
:Patient6 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 64 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 6" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient7
:Patient7 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 65 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 7" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient8
:Patient8 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 66 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 8" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Patient9
:Patient9 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 56 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 9" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#PatientRestraint
:PatientRestraint rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10053316 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "patient restraint" ;
                  rdfs:label "patient restraint" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Pharmacokinetic_interaction_of_VA_and_Q
:Pharmacokinetic_interaction_of_VA_and_Q rdf:type owl:NamedIndividual ,
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect_Mechanism> ,
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Literature_information> ;
                                         mp:references :Ref.15 ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The authors postulated a pharmacokinetic  interaction between valproic acid and quetiapine  had resulted in the inhibition of CYP3A4, one of  quetiapine’s main metabolic pathways" ;
                                         rdfs:label "Pharmacokinetic interaction of VA and Q" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Prof._Alfonso_Carvajal
:Prof._Alfonso_Carvajal rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Author> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_affiliation> "Spain" ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_first_name> "Alfonso" ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_last_name> "Carvajal" ;
                        rdfs:label "Prof. Alfonso Carvajal" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#QDose1
:QDose1 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 200 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "200 mg" ;
        rdfs:label "Q dose 1a" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#QDose10
:QDose10 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 200 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "200 mg" ;
         rdfs:label "Q dose 10" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#QDose11
:QDose11 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 50 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "50 mg" ;
         rdfs:label "Q dose 11a" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#QDose12
:QDose12 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 300 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "300 mg" ;
         rdfs:label "Q dose 12a" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#QDose13
:QDose13 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 50 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "50 mg" ;
         rdfs:label "Q dose 13a" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#QDose14
:QDose14 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "“high doses” of both drugs" ;
         rdfs:label "Q dose 14" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#QDose17
:QDose17 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 200 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "200 mg" ;
         rdfs:label "Q dose 17" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#QDose18
:QDose18 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 700 ,
                                                                   800 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "700 mg" ,
                                                                              "800 mg" ;
         rdfs:label "Q dose 18" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#QDose19
:QDose19 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 600 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "600 mg" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_partial_dechallenge_process> "true"^^xsd:boolean ;
         rdfs:label "Q dose 19" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#QDose2
:QDose2 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 200 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true" ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "200 mg" ;
        rdfs:label "Q dose 2" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#QDose20
:QDose20 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 400 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "400 mg" ;
         rdfs:label "Q dose 20" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#QDose3
:QDose3 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 200 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "200 mg" ;
        rdfs:label "Q dose 3" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#QDose4
:QDose4 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 500 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true" ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "500 mg" ;
        rdfs:label "Q dose 4" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#QDose5
:QDose5 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 50 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true"^^xsd:boolean ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "50 mg" ;
        rdfs:label "Q dose 5" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#QDose6
:QDose6 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 50 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "50 mg" ;
        rdfs:label "Q dose 6a" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#QDose7
:QDose7 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 100 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "100 mg" ;
        rdfs:label "Q dose 7a" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#QDose8
:QDose8 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "200 mg/day / Quetiapine up to 500 mg/day after surgery" ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 200 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true"^^xsd:boolean ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "200 mg" ;
        rdfs:label "Q dose 8" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#QDose9
:QDose9 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 100 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "100 mg" ;
        rdfs:label "Q dose 9a" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_dose_11b
:Q_dose_11b rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 400 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "400 mg" ;
            rdfs:label "Q dose 11b" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_dose_12b
:Q_dose_12b rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 800 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true"^^xsd:boolean ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "800 mg" ;
            rdfs:label "Q dose 12b" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_dose_13b
:Q_dose_13b rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 500 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "500 mg" ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_partial_dechallenge_process> "true"^^xsd:boolean ;
            rdfs:label "Q dose 13b" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_dose_1b
:Q_dose_1b rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 400 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true"^^xsd:boolean ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "400 mg" ;
           rdfs:label "Q dose 1b" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_dose_6b
:Q_dose_6b rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 100 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "100 mg" ;
           rdfs:label "Q dose 6b" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_dose_7b
:Q_dose_7b rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 950 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true"^^xsd:boolean ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "950 mg" ;
           rdfs:label "Q dose 7b" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_dose_9b
:Q_dose_9b rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 900 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "900 mg" ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_partial_dechallenge_process> "true"^^xsd:boolean ;
           rdfs:label "Q dose 9b" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_usage_for_Report1
:Q_usage_for_Report1 rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :QDose1 ,
                                                                                      :Q_dose_1b ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
                     rdfs:label "Q usage for report 1" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_usage_for_Report10
:Q_usage_for_Report10 rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :QDose10 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
                      rdfs:label "Q usage for report 10" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_usage_for_Report11
:Q_usage_for_Report11 rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :QDose11 ,
                                                                                       :Q_dose_11b ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
                      rdfs:label "Q usage for report 11" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_usage_for_Report12
:Q_usage_for_Report12 rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :QDose12 ,
                                                                                       :Q_dose_12b ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
                      rdfs:label "Q usage for report 12" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_usage_for_Report13
:Q_usage_for_Report13 rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :QDose13 ,
                                                                                       :Q_dose_13b ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
                      rdfs:label "Q usage for report 13" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_usage_for_Report14
:Q_usage_for_Report14 rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :QDose14 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
                      rdfs:label "Q usage for report 14" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_usage_for_Report17
:Q_usage_for_Report17 rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :QDose17 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
                      rdfs:label "Q usage for report 17" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_usage_for_Report18
:Q_usage_for_Report18 rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :QDose18 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
                      rdfs:label "Q usage for report 18" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_usage_for_Report19
:Q_usage_for_Report19 rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :QDose19 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
                      rdfs:label "Q usage for report 19" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_usage_for_Report2
:Q_usage_for_Report2 rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :QDose2 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
                     rdfs:label "Q usage for report 2" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_usage_for_Report20
:Q_usage_for_Report20 rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :QDose20 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
                      rdfs:label "Q usage for report 20" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_usage_for_Report3
:Q_usage_for_Report3 rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :QDose3 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
                     rdfs:label "Q usage for report 3" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_usage_for_Report4
:Q_usage_for_Report4 rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :QDose4 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
                     rdfs:label "Q usage for report 4" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_usage_for_Report5
:Q_usage_for_Report5 rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :QDose5 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
                     rdfs:label "Q usage for report 5" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_usage_for_Report6
:Q_usage_for_Report6 rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :QDose6 ,
                                                                                      :Q_dose_6b ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
                     rdfs:label "Q usage for report 6" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_usage_for_Report7
:Q_usage_for_Report7 rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :QDose7 ,
                                                                                      :Q_dose_7b ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
                     rdfs:label "Q usage for report 7" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_usage_for_Report8
:Q_usage_for_Report8 rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :QDose8 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
                     rdfs:label "Q usage for report 8" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Q_usage_for_Report9
:Q_usage_for_Report9 rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :QDose9 ,
                                                                                      :Q_dose_9b ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ;
                     rdfs:label "Q usage for report 9" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Quetiapine_Mechanism
:Quetiapine_Mechanism rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Mechanism> ;
                      mp:references :Ref.1 ,
                                    :Ref.2 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Quetiapine is an atypical antipsychotic, with  antagonistic activity for serotonin 5-HT 1A /5-HT 2 ,  dopamine D 1 /D 2 , histamine H 1 and noradrenaline α 1 and α 2 receptors" ;
                      rdfs:label "Quetiapine Mechanism" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#RecommendedDoseOfQInAdjunctWithVA
:RecommendedDoseOfQInAdjunctWithVA rdf:type owl:NamedIndividual ,
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ,
                                                                                                  :valproicAcid ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "400-800 mg per day" ;
                                   rdfs:label "Recommended dose of Q in adjunct with VA" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.1
:Ref.1 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Electronic Medicines Compendium. Summary  of Product Characteristics for quetiapine  (Seroquel 25 mg, 100 mg, 200 mg, 300 mg  film-coated tablets). Available from:  https://www.medicines.org.uk/emc/  medicine/2295. Accessed: 11 January 2017.  " ;
       rdfs:label "Ref.1" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.10
:Ref.10 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Winter HR, DeVane CL, Figueroa C,  Ennis DJ, Hamer-Maansson JE, Davis  PC, et al. Open-label steady-state  pharmacokinetic drug interaction study on  co-administered quetiapine fumarate and  divalproex sodium in patients with  schizophrenia, schizoaffective disorder, or  bipolar disorder. Hum Psychopharmacol.  2007;22(7):469-76. " ;
        rdfs:label "Ref.10" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.11
:Ref.11 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Aichhorn W, Marksteiner J, Walch T,  Zernig G, Saria A, Kemmler G. Influence of age, gender, body weight and valproate  comedication on quetiapine plasma  concentrations. Int Clin Psychopharmacol.  2006;21(2):81-5. " ;
        rdfs:label "Ref.11" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.12
:Ref.12 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Stockley’s, Drug, Interactions. Quetiapine +  Valproate [Online]. London: Pharmaceutical Press;  2016 [Available from:  http://www.medicinescomplete.com/. Accessed:  11 January 2017. " ;
        rdfs:label "Ref.12" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.13
:Ref.13 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Erdoğan S, Çelikel FÇ. Massive creatine  kinase and hepatic enzyme elevation due to  quetiapine and valproic acid treatment: a  case report. Archives of Neuropsychiatry  2011;53(4):238-40. " ;
        rdfs:label "Ref.13" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.14
:Ref.14 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Reiche I, Tröger U, Postel SC, Wolf R, BodeBöger SM. Valproic acid-induced myopathy in a  patient with schizoaffective disorder. J Clin  Psychopharmacol. 2009;29(4):402-3. " ;
        rdfs:label "Ref.14" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.15
:Ref.15 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Jahn H, Kiefer F, Arlt J. Rhabdomyolysis  with quetiapine. German Journal of  Psychiatry 2008;11(2):79-80.  " ;
        rdfs:label "Ref.15" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.16
:Ref.16 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "De Dios C, Fudio S, Lorenzo A. Reversible  parkinsonism and cognitive decline due to a  possible interaction of valproic acid and  quetiapine. J Clin Pharm Ther.  2011;36(3):430-2.  " ;
        rdfs:label "Ref.16" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.17
:Ref.17 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Larsen EP, Ostergaard JR. Valproate-induced  hyperammonemia in juvenile ceroid  lipofuscinosis (Batten disease). Seizure.  2014;23(6):429-34.  " ;
        rdfs:label "Ref.17" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.18
:Ref.18 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Wu CY, Mitchell SR, Seyfried LS. Quetiapineinduced hyperglycemic crisis and severe  hyperlipidemia: a case report and review of  the  literature. Psychosomatics.55(6):686-91.  " ;
        rdfs:label "Ref.18" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.19
:Ref.19 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Juhlin K, Star K, Norén GN. A method for  data-driven exploration to pinpoint key  features in medical data and facilitate expert  review. Pharmacoepidemiol Drug Saf.  2017;26(10):1256-65.  20.  Vella T, Mifsud J. Interactions between  valproic acid and quetiapine/olanzapine  in the treatment of bipolar disorder and  the role of therapeutic drug monitoring.  J Pharm Pharmacol. 2014;66(6):747-59.  " ;
        rdfs:label "Ref.19" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.2
:Ref.2 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "US Food and Drug Administration.  Product label for quetiapine  (Seroquel ® ). Available from:  http://www.accessdata.fda.gov/dr ugsatfda_docs/  label/2016/020639s064lbl.pdf.  Accessed: 11 January 2017. " ;
       rdfs:label "Ref.2" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.20
:Ref.20 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Vella T, Mifsud J. Interactions between  valproic acid and quetiapine/olanzapine  in the treatment of bipolar disorder and  the role of therapeutic drug monitoring.  J Pharm Pharmacol. 2014;66(6):747-59.  " ;
        rdfs:label "Ref.20" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.21
:Ref.21 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Hohenegger M. Drug induced  rhabdomyolysis. Curr Opin Pharmacol.  2012;12(3):335-9.  " ;
        rdfs:label "Ref.21" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.22
:Ref.22 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Pelonero AL, Levenson JL, Pandurangi  AK. Neuroleptic malignant syndrome: a  review. Psychiatr serv.  1998;49(9):1163-72.  " ;
        rdfs:label "Ref.22" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.23
:Ref.23 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Habermeyer B, Rabovsky K, Jentzsch C,  Pinhard K, Müller-Spahn F. Cervical  dystonia due to interaction of valproic  acid and quetiapine. J Clin  Psychopharmacol. 2007;27(4):396-7. " ;
        rdfs:label "Ref.23" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.24
:Ref.24 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Hartz SM, Pato CN, Medeiros H,  Cavazos-Rehg P, Sobell JL, Knowles JA,  et al. Comorbidity of severe psychotic  disorders with measures of substance  use. JAMA psychiatry. 2014;71(3):248-54.  " ;
        rdfs:label "Ref.24" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.25
:Ref.25 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Messina ES, Tyndale RF, Sellers EM. A  Major Role for CYP2A6 in Nicotine Coxidation by human liver microsomes. J  Pharmacol Exp Ther.  1997;282(3):1608-14.  " ;
        rdfs:label "Ref.25" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.26
:Ref.26 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Kiang TK, Ho PC, Anari MR, Tong V,  Abbott FS, Chang TK. Contribution of  CYP2C9, CYP2A6, and CYP2B6 to  valproic acid metabolism in hepatic  microsomes from individuals with the  CYP2C9*1/*1 genotype. Toxicol Sci.  2006;94(2):261-71. " ;
        rdfs:label "Ref.26" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.3
:Ref.3 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Sachs G, Chengappa KN, Suppes T,  Mullen JA, Brecher M, Devine NA, et al.  Quetiapine with lithium or divalproex for  the treatment of bipolar mania: a  randomized, double-blind, placebocontrolled study. Bipolar Disord.  2004;6(3):213-23. " ;
       rdfs:label "Ref.3" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.4
:Ref.4 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Sokolski KN, Denson TF. Adjunctive  quetiapine in bipolar patients partially  responsive to lithium or valproate. Prog  Neuropsychopharmacol Biol Psychiatry.  2003;27(5):863-6. " ;
       rdfs:label "Ref.4" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.5
:Ref.5 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Suppes T, Vieta E, Gustafsson U, Ekholm  B. Maintenance treatment with quetiapine  when combined with either lithium or  divalproex in bipolar I disorder: analysis of  two large randomized, placebo-controlled  trials. Depress Anxiety.  2013;30(11):1089-98. " ;
       rdfs:label "Ref.5" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.6
:Ref.6 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Yatham LN, Paulsson B, Mullen J, Vågerö  AM. Quetiapine versus placebo in  combination with lithium or divalproex for  the treatment of bipolar mania. J Clin  Psychopharmacol. 2004;24(6):599-606. " ;
       rdfs:label "Ref.6" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.7
:Ref.7 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Haeberle A, Greil W, Russmann S, Grohmann  R. Mono- and combination drug therapies in  hospitalized patients with bipolar  depression. Data from the European drug surveillance program AMSP. BMC  Psychiatry. 2012;12(1):153. " ;
       rdfs:label "Ref.7" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.8
:Ref.8 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Sanofi. Product Information for valproic acid  (Epilim ® ). Available from:  http://www.sanofi.com.au/products/  aus_pi_epilim.pdf. Accessed: 11 January  2017. " ;
       rdfs:label "Ref.8" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Ref.9
:Ref.9 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Electronic Medicines Compendium.  Summary of Product Characteristics for  valproic acid (Depakote ® ). Available from:  https://www.medicines.org.uk/emc/  medicine/25929. Accessed: 11 January  2017. " ;
       rdfs:label "Ref.9" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report1
:Report1 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :CaseReportInfo1 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :bloodCreatinePhosphokinaseIncreased ,
                                                                                  :creatineKinaseMbIncreased ,
                                                                                  :hepaticEnzymesIncreased ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :lithium ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient1 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :quetiapine ,
                                                                                        :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Q_usage_for_Report1 ,
                                                                                       :VA_usage_for_Report1 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnset1 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
         rdfs:label "Report 1" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report10
:Report10 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :CaseReportInfo10 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :affectLability ,
                                                                                   :depressedLevelOfConsciousness ,
                                                                                   :inappropriateScheduleOfDrugAdministration ,
                                                                                   :pneumonia ,
                                                                                   :pyrexia ,
                                                                                   :somnolence ,
                                                                                   :treatmentNoncompliance ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient10 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :quetiapine ,
                                                                                         :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Q_usage_for_Report10 ,
                                                                                        :VA_usage_for_Report10 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnset10 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "hospitalization for treatment" ;
          rdfs:label "Report 10" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report11
:Report11 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :CaseReportInfo11 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :depressedLevelOfConsciousness ,
                                                                                   :gaitDisturbance ,
                                                                                   :overdose ,
                                                                                   :pain ,
                                                                                   :physicalAssault ,
                                                                                   :speechDisorder ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient11 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :quetiapine ,
                                                                                         :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Q_usage_for_Report11 ,
                                                                                        :VA_usage_for_Report11 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnset11 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_rechallenge_outcome> "positive rechallenge - condition appeared again" ;
          rdfs:label "Report 11" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report12
:Report12 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :CaseReportInfo12 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :cognitiveDeterioration ,
                                                                                   :depressedLevelOfConsciousness ,
                                                                                   :hemiparesis ,
                                                                                   :memoryDeficit ,
                                                                                   :parkinsonism ,
                                                                                   :temporalDisorientation ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interacting_drug> :quetiapine ,
                                                                                     :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient12 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :quetiapine ,
                                                                                         :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Q_usage_for_Report12 ,
                                                                                        :VA_usage_for_Report12 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnset12 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
          rdfs:label "Report 12" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report13
:Report13 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :CaseReportInfo13 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :alteredStateOfConsciousness ,
                                                                                   :bloodThyroidStimulatingHormoneDecreased ,
                                                                                   :depressedLevelOfConsciousness ,
                                                                                   :drugInteraction ,
                                                                                   :parkinsonism ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :alfuzosin ,
                                                                                     :finasteride ,
                                                                                     :lithium ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interacting_drug> :aripiprazole ,
                                                                                     :quetiapine ,
                                                                                     :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient13 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :quetiapine ,
                                                                                         :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Q_usage_for_Report13 ,
                                                                                        :VA_usage_for_Report13 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_unconfirmed_adverse_effect> :coma ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnset13 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after dose reduction" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_partial_dechallenge_outcome> "positive - condition not applied" ;
          rdfs:label "Report 13" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report14
:Report14 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :coma ,
                                                                                   :depressedLevelOfConsciousness ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient14 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :quetiapine ,
                                                                                         :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Q_usage_for_Report14 ,
                                                                                        :VA_usage_for_Report14 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :lorazepam ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_unconfirmed_adverse_effect> :dehydration ;
          rdfs:label "Report 14" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report15
:Report15 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :coma ,
                                                                                   :convulsions ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient15 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :quetiapine ,
                                                                                         :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :sertraline ;
          rdfs:label "Report 15" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report16
:Report16 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :coma ,
                                                                                   :hypotension ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient16 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :quetiapine ,
                                                                                         :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :nifedipine ;
          rdfs:label "Report 16" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report17
:Report17 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :CaseReportInfo17 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :anticonvulsantDrugLevelAboveTherapeutic ,
                                                                                   :coma ,
                                                                                   :drowsiness ,
                                                                                   :hyperammonemia ,
                                                                                   :hyperammonemicEncephalopathy ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient17 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :quetiapine ,
                                                                                         :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Q_usage_for_Report17 ,
                                                                                        :VA_usage_for_Report17 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :oxcarbazepine ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnset17 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
          rdfs:label "Report 17" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report18
:Report18 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :CaseReportInfo18 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :bloodCholesterolIncreased ,
                                                                                   :coma ,
                                                                                   :diabetesMellitus ,
                                                                                   :diabeticKetoacidosis ,
                                                                                   :drugInteraction ,
                                                                                   :hypercapnia ,
                                                                                   :hyperglycaemia ,
                                                                                   :hyperosmolarState ,
                                                                                   :hypertriglyceridemia ,
                                                                                   :hypoxia ,
                                                                                   :lipidsIncreased ,
                                                                                   :weightIncreased ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interacting_drug> :quetiapine ,
                                                                                     :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient18 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :quetiapine ,
                                                                                         :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Q_usage_for_Report18 ,
                                                                                        :VA_usage_for_Report18 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :lorazepam ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnset18 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
          rdfs:label "Report 18" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report19
:Report19 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :CaseReportInfo19 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :disorientation ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient19 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :quetiapine ,
                                                                                         :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Q_usage_for_Report19 ,
                                                                                        :VA_usage_for_Report19 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :lithium ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnset19 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
          rdfs:label "Report 19" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report2
:Report2 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :CaseReportInfo2 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :bloodCreatinePhosphokinaseIncreased ,
                                                                                  :drugClearanceDecreased ,
                                                                                  :drugInteraction ,
                                                                                  :musclePain ,
                                                                                  :muscleWeakness ,
                                                                                  :myoglobinBloodIncreased ,
                                                                                  :myopathy ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :acetylsalicylicAcid ,
                                                                                    :furosemide ,
                                                                                    :levothyroxine ,
                                                                                    :nifedipine ,
                                                                                    :torasemide ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient2 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :quetiapine ,
                                                                                        :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Q_usage_for_Report2 ,
                                                                                       :VA_usage_for_Report2 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :pipamperone ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnset2 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_rechallenge_outcome> "negative rechallenge - condition not appeared" ;
         rdfs:label "Report 2" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report20
:Report20 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :CaseReportInfo20 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :concentrationImpaired ,
                                                                                   :disorientation ,
                                                                                   :dizziness ,
                                                                                   :nausea ,
                                                                                   :thinkingAbnormal ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient20 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :quetiapine ,
                                                                                         :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Q_usage_for_Report20 ,
                                                                                        :VA_usage_for_Report20 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :fluvoxamine ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnset20 ;
          rdfs:label "Report 20" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report3
:Report3 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :creatineKinaseMbIncreased ,
                                                                                  :musclePain ,
                                                                                  :rhabdomyolysis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient3 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :quetiapine ,
                                                                                        :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Q_usage_for_Report3 ,
                                                                                       :VA_usage_for_Report3 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :venlafaxine ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
         rdfs:label "Report 3" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report4
:Report4 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :CaseReportInfo4 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :bodyTemperatureIncreased ,
                                                                                  :creatineKinaseMbIncreased ,
                                                                                  :drugInteraction ,
                                                                                  :malaise ,
                                                                                  :musclePain ,
                                                                                  :muscleRigidity ,
                                                                                  :muscleWeakness ,
                                                                                  :musculoskeletalStiffness ,
                                                                                  :rhabdomyolysis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interacting_drug> :quetiapine ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient4 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Q_usage_for_Report4 ,
                                                                                       :VA_usage_for_Report4 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnset4 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
         rdfs:label "Report 4" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report5
:Report5 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :CaseReportInfo5 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :bronchopneumonia ,
                                                                                  :renalFailureAcute ,
                                                                                  :rhabdomyolysis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :delorazepam ,
                                                                                    :flurazepam ,
                                                                                    :paroxetine ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient5 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :quetiapine ,
                                                                                        :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Q_usage_for_Report5 ,
                                                                                       :VA_usage_for_Report5 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :paliperidone ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnset5 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
         rdfs:label "Report 5" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report6
:Report6 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :CaseReportInfo6 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :acidosisMetabolic ,
                                                                                  :disorientation ,
                                                                                  :extrapyramidalDisorder ,
                                                                                  :hypotension ,
                                                                                  :neurolepticMalignantSyndrome ,
                                                                                  :renalFailureAcute ,
                                                                                  :rhabdomyolysis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :amlodipine ,
                                                                                    :indapamide ,
                                                                                    <http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#hydrochlorothiazide/lisinopril> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interacting_drug> :quetiapine ,
                                                                                    :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient6 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :quetiapine ,
                                                                                        :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Q_usage_for_Report6 ,
                                                                                       :VA_usage_for_Report6 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_unconfirmed_adverse_effect> :fever ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnset6 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
         rdfs:label "Report 6" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report7
:Report7 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :CaseReportInfo7 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :confusion ,
                                                                                  :depressedLevelOfConsciousness ,
                                                                                  :dysarthria ,
                                                                                  :fever ,
                                                                                  :muscleSpasticity ,
                                                                                  :neurolepticMalignantSyndrome ,
                                                                                  :rigors ,
                                                                                  :tremor ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient7 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :quetiapine ,
                                                                                        :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Q_usage_for_Report7 ,
                                                                                       :VA_usage_for_Report7 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :pipamperone ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnset7 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
         rdfs:label "Report 7" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report8
:Report8 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :CaseReportInfo8 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :depressedLevelOfConsciousness ,
                                                                                  :diabetesInsipidus ,
                                                                                  :extrapyramidalDisorder ,
                                                                                  :hypernatraemia ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :ceftriaxone ,
                                                                                    :heparin ,
                                                                                    :metronidazole ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interacting_drug> :quetiapine ,
                                                                                    :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient8 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :quetiapine ,
                                                                                        :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Q_usage_for_Report8 ,
                                                                                       :VA_usage_for_Report8 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :lithium ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery after drug withdrawal" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_rechallenge_outcome> "negative rechallenge - condition not appeared" ;
         rdfs:label "Report 8" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Report9
:Report9 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_free_text_reporting_element> :CaseReportInfo9 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :consciousnessDecreased ,
                                                                                  :drugInteraction ,
                                                                                  :prescribedOverdose ,
                                                                                  :restlessness ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :acetylsalicylicAcid ,
                                                                                    :clopidogrel ,
                                                                                    :pantoprazole ,
                                                                                    :ramipril ,
                                                                                    <http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#hydrochlorothiazide/valsartan> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient9 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :quetiapine ,
                                                                                        :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Q_usage_for_Report9 ,
                                                                                       :VA_usage_for_Report9 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :perazine ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_unconfirmed_adverse_effect> :depressedLevelOfConsciousness ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnset9 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_partial_dechallenge_outcome> "positive - condition not applied" ;
         rdfs:label "Report 9" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#ReportsFocusingOndrug-drugInteractionsForQAndVA
:ReportsFocusingOndrug-drugInteractionsForQAndVA rdf:type owl:NamedIndividual ,
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibaseForQAndVAco-reportedAsSuspectedOrInteracting ;
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interacting_drug> :quetiapine ,
                                                                                                                            :valproicAcid ;
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 50 ;
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                 rdfs:label "Reports focusing on drug-drug interactions for Q and VA" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#ReportsFromAustralia
:ReportsFromAustralia rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Australia" ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                      rdfs:label "Reports from Australia" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#ReportsFromCanada
:ReportsFromCanada rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Canada" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                   rdfs:label "Reports from Canada" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#ReportsFromDenmark
:ReportsFromDenmark rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Denmark" ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                    rdfs:label "Reports from Denmark" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#ReportsFromGermany
:ReportsFromGermany rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 4 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Germany" ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                    rdfs:label "Reports from Germany" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#ReportsFromItaly
:ReportsFromItaly rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Italy" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                  rdfs:label "Reports from Italy" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#ReportsFromSouthKorea
:ReportsFromSouthKorea rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/South_Korea" ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                       rdfs:label "Reports from South Korea" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#ReportsFromSpain
:ReportsFromSpain rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Spain" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                  rdfs:label "Reports from Spain" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#ReportsFromSwitzerland
:ReportsFromSwitzerland rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 3 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Switzerland" ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                        rdfs:label "Reports from Switzerland" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#ReportsFromTurkey
:ReportsFromTurkey rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Turkey" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                   rdfs:label "Reports from Turkey" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#ReportsFromUSA
:ReportsFromUSA rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 5 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/United_States" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                rdfs:label "Reports from USA" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_in_VigiBase
:Reports_in_VigiBase rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """As of December 2016 there were 1522 ICSRs  of quetiapine and valproic acid, co-reported as  suspected or interacting, in VigiBase. During a  signal detection screening focusing on drugdrug-interactions, 50 quetiapine-valproic acidinteraction combinations were highlighted. To limit the cases to a number manageable  for manual assessment, we performed an  automatic case series features comparison  using shrinkage odds ratios (see vigiPoint 19 ).  Five MedDRA preferred terms (PTs) were  identified as relevant and selected: blood  creatine phosphokinase increased, coma,  depressed level of consciousness,  disorientation and rhabdomyolysis. Suicide  attempts were excluded, along with cases  which contained over three co-suspects, to  minimize polypharmacy confounding. Twenty  cases remained; the full results of the analysis  are available upon request. The 20 reports originated from the United  States (5 cases), Germany (4), Switzerland  (3), Canada (2), Australia, Denmark, Italy,  Turkey, South Korea and Spain (1 case each).  Patient sex was mostly male (13 vs 7), with  an average age of 49 years. The indication  given was: bipolar disorder in seven cases,  schizoaffective disorder in two, paranoid  schizophrenia in one, psychotic  disorder/psychosis in two, depression in two,  and patient restraint, Batten disease and  posttraumatic stress disorder in one case  each. Five cases reported “Blood creatine  phosphokinase increased”, five “Coma”, eight  “Depressed level of consciousness”, four  “Disorientation” and four “Rhabdomyolysis”,  all at PT level. Most cases (15/20) were  reported as serious. Two groups of reported events can be  identified: musculoskeletal and psychiatric.  For these two groups, time to onset, de- and  re-challenges, and outcomes were determined for a given reported MedDRA PT. When  two events of the same group were in the same  report, the more severe of them was selected. 
Musculoskeletal reported adverse events PTs: 
Rhabdomyolysis/blood creatinine  phosphokinase increased Six cases (1 to 6 in the table), in two of  which  quetiapine and valproic acid were reported as  interacting, and one case which included the term  “Drug interaction”. The highest dose of Quetiapine  per patient ranged from 50-500 mg/day, while the  highest for valproic acid was 250-1500 mg/day.  Time to onset ranged from 4 days after valproic  acid introduction to 75 days (median 11 days).  The outcome was recovery in all six  patients. Case 6 features also disorientation, a  neuropsychiatric event (see below), but CPK  measurements allowed for rhabdomyolysis to be  selected as the main term.  
Neuropsychiatric reported adverse events PTs: 
Depressed level of consciousness/Coma Twelve cases in total (7 to 18 in the table). In four,  quetiapine and valproic acid were reported as  interacting. The highest dose of quetiapine per  patient ranged from 200-950 mg/day, while the  highest for valproic acid was 300-2500 mg/day.  Time to onset ranged from 1 day after valproic acid introduction to 16 months (median 17 days). The  outcome was recovery in seven patients and  unknown with reaction abated in two. In the narrative of case 7 there is a mention of CPK  increase, but the information is incomplete.  Therefore, coma was chosen as main term. PT: Disorientation Two cases (19 and 20 in the table). Neither reported the two drugs as interacting. The highest  dose of Quetiapine per patient ranged from 400-600 mg/day, while the highest for valproic acid was 1.5-500 mg/ day (one of which is possibly 1.5  grams due to entry mistake). Time to onset was 17  days and 3 years. The outcome was recovery in both cases.""" ;
                     rdfs:label "Reports in VigiBase" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_remaining_for_MedDRA_PTs
:Reports_remaining_for_MedDRA_PTs rdf:type owl:NamedIndividual ,
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :ReportsFocusingOndrug-drugInteractionsForQAndVA ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_average_age> 49 ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 20 ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_men> 13 ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_women> 7 ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                  rdfs:label "Reports remaining for MedDRA PTs" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_Batten_disease_as_indication
:Reports_with_Batten_disease_as_indication rdf:type owl:NamedIndividual ,
                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :BattenDisease ;
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                           rdfs:label "Reports with Batten disease as indication" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_Depressed_level_of_conciousness_as_adverse_event_at_PT_level
:Reports_with_Depressed_level_of_conciousness_as_adverse_event_at_PT_level rdf:type owl:NamedIndividual ,
                                                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_unconfirmed_adverse_effect> :depressedLevelOfConsciousness ;
                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 8 ;
                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                           rdfs:label "Reports with Depressed level of conciousness as adverse event at PT level" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_Disorientation_as_adverse_event_at_PT_level
:Reports_with_Disorientation_as_adverse_event_at_PT_level rdf:type owl:NamedIndividual ,
                                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_unconfirmed_adverse_effect> :disorientation ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 4 ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                          rdfs:label "Reports with Disorientation as adverse event at PT level" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_Rhabdomyolysis_as_adverse_event_at_PT_level
:Reports_with_Rhabdomyolysis_as_adverse_event_at_PT_level rdf:type owl:NamedIndividual ,
                                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_unconfirmed_adverse_effect> :rhabdomyolysis ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 4 ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                          rdfs:label "Reports with Rhabdomyolysis as adverse event at PT level" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_bipolar_disorder_as_indication
:Reports_with_bipolar_disorder_as_indication rdf:type owl:NamedIndividual ,
                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :BipolarDisorder ;
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 7 ;
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                             rdfs:label "Reports with bipolar disorder as indication" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_dipression_as_indication
:Reports_with_dipression_as_indication rdf:type owl:NamedIndividual ,
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :Depression ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                       rdfs:label "Reports with depression as indication" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_patient_restraint_as_indication
:Reports_with_patient_restraint_as_indication rdf:type owl:NamedIndividual ,
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :PatientRestraint ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                              rdfs:label "Reports with patient restraint as indication" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_posttraumatic_stress_disorder_as_indication
:Reports_with_posttraumatic_stress_disorder_as_indication rdf:type owl:NamedIndividual ,
                                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :posttraumaticStressDisorder ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                          rdfs:label "Reports with posttraumatic stress disorder as indication" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_schizoaffective_disorder_as_indication
:Reports_with_schizoaffective_disorder_as_indication rdf:type owl:NamedIndividual ,
                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :SchizoaffectiveDisorder ;
                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                     rdfs:label "Reports with schizoaffective disorder as indication" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_schizophrenia_as_indication
:Reports_with_schizophrenia_as_indication rdf:type owl:NamedIndividual ,
                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :paranoidSchizophrenia ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                          rdfs:label "Reports with paranoid schizophrenia as indication" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#SchizoaffectiveDisorder
:SchizoaffectiveDisorder rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "F25" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10039621 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "schizoaffective disorder" ;
                         rdfs:label "schizoaffective disorder" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Schizophrenia
:Schizophrenia rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "F20" ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10039626 ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "schizophrenia" ;
               rdfs:label "schizophrenia" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Smaller_study
:Smaller_study rdf:type owl:NamedIndividual ,
                        <http://purl.obolibrary.org/obo/OAE_0001197> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ,
                                                                              :valproicAcid ;
               mp:references :Ref.11 ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Conversely, a smaller study showed an increase in up to 77% of plasma quetiapine concentrations, when given together with valproic acid.11" ;
               rdfs:label "Smaller study" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#TimeToOnset1
:TimeToOnset1 rdf:type owl:NamedIndividual ,
                       <http://www.w3.org/2006/time#DurationDescription> ;
              <http://www.w3.org/2006/time#nominalPosition> "days" ;
              <http://www.w3.org/2006/time#numericPosition> 11 ;
              rdfs:label "Time to onset 1" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#TimeToOnset10
:TimeToOnset10 rdf:type owl:NamedIndividual ,
                        <http://www.w3.org/2006/time#DurationDescription> ;
               <http://www.w3.org/2006/time#nominalPosition> "days" ;
               <http://www.w3.org/2006/time#numericPosition> 5 ;
               rdfs:label "Time to onset 10" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#TimeToOnset11
:TimeToOnset11 rdf:type owl:NamedIndividual ,
                        <http://www.w3.org/2006/time#DurationDescription> ;
               <http://www.w3.org/2006/time#nominalPosition> "days" ;
               <http://www.w3.org/2006/time#numericPosition> 12 ;
               rdfs:label "Time to onset 11" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#TimeToOnset12
:TimeToOnset12 rdf:type owl:NamedIndividual ,
                        <http://www.w3.org/2006/time#DurationDescription> ;
               <http://www.w3.org/2006/time#nominalPosition> "days" ;
               <http://www.w3.org/2006/time#numericPosition> 17 ;
               rdfs:label "Time to onset 12" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#TimeToOnset13
:TimeToOnset13 rdf:type owl:NamedIndividual ,
                        <http://www.w3.org/2006/time#DurationDescription> ;
               <http://www.w3.org/2006/time#nominalPosition> "days" ;
               <http://www.w3.org/2006/time#numericPosition> 19 ;
               rdfs:label "Time to onset 13" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#TimeToOnset17
:TimeToOnset17 rdf:type owl:NamedIndividual ,
                        <http://www.w3.org/2006/time#DurationDescription> ;
               <http://www.w3.org/2006/time#nominalPosition> "weeks" ;
               <http://www.w3.org/2006/time#numericPosition> 3 ;
               rdfs:label "Time to onset 17" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#TimeToOnset18
:TimeToOnset18 rdf:type owl:NamedIndividual ,
                        <http://www.w3.org/2006/time#DurationDescription> ;
               <http://www.w3.org/2006/time#nominalPosition> "months" ;
               <http://www.w3.org/2006/time#numericPosition> 16 ;
               rdfs:label "Time to onset 18" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#TimeToOnset19
:TimeToOnset19 rdf:type owl:NamedIndividual ,
                        <http://www.w3.org/2006/time#DurationDescription> ;
               <http://www.w3.org/2006/time#nominalPosition> "days" ;
               <http://www.w3.org/2006/time#numericPosition> 17 ;
               rdfs:label "Time to onset 19" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#TimeToOnset2
:TimeToOnset2 rdf:type owl:NamedIndividual ,
                       <http://www.w3.org/2006/time#DurationDescription> ;
              <http://www.w3.org/2006/time#nominalPosition> "days" ;
              <http://www.w3.org/2006/time#numericPosition> 4 ;
              rdfs:label "Time to onset 2" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#TimeToOnset20
:TimeToOnset20 rdf:type owl:NamedIndividual ,
                        <http://www.w3.org/2006/time#DurationDescription> ;
               <http://www.w3.org/2006/time#nominalPosition> "years" ;
               <http://www.w3.org/2006/time#numericPosition> 3 ;
               rdfs:label "Time to onset 20" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#TimeToOnset4
:TimeToOnset4 rdf:type owl:NamedIndividual ,
                       <http://www.w3.org/2006/time#DurationDescription> ;
              <http://www.w3.org/2006/time#nominalPosition> "months" ;
              <http://www.w3.org/2006/time#numericPosition> 2.5 ;
              rdfs:label "Time to onset 4" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#TimeToOnset5
:TimeToOnset5 rdf:type owl:NamedIndividual ,
                       <http://www.w3.org/2006/time#DurationDescription> ;
              <http://www.w3.org/2006/time#nominalPosition> "months" ;
              <http://www.w3.org/2006/time#numericPosition> 2 ;
              rdfs:label "Time to onset 5" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#TimeToOnset6
:TimeToOnset6 rdf:type owl:NamedIndividual ,
                       <http://www.w3.org/2006/time#DurationDescription> ;
              <http://www.w3.org/2006/time#nominalPosition> "days" ;
              <http://www.w3.org/2006/time#numericPosition> 4 ;
              rdfs:label "Time to onset 6" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#TimeToOnset7
:TimeToOnset7 rdf:type owl:NamedIndividual ,
                       <http://www.w3.org/2006/time#DurationDescription> ;
              <http://www.w3.org/2006/time#nominalPosition> "months" ;
              <http://www.w3.org/2006/time#numericPosition> 1 ;
              rdfs:label "Time to onset 7" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#TimeToOnset9
:TimeToOnset9 rdf:type owl:NamedIndividual ,
                       <http://www.w3.org/2006/time#DurationDescription> ;
              <http://www.w3.org/2006/time#nominalPosition> "days" ;
              <http://www.w3.org/2006/time#numericPosition> 1 ;
              rdfs:label "Time to onset 9" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Uppsala_Monitoring_Centre
:Uppsala_Monitoring_Centre rdf:type owl:NamedIndividual ,
                                    <http://www.w3.org/ns/prov#Organization> ;
                           rdfs:label "Uppsala Monitoring Centre" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VADose1
:VADose1 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1500 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "1500 mg" ;
         rdfs:label "VA dose 1" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VADose10
:VADose10 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1000 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "1000 mg" ;
          rdfs:label "VA dose 10" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VADose11
:VADose11 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 700 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "700 mg" ;
          rdfs:label "VA dose 11" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VADose12
:VADose12 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1000 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "1000 mg" ;
          rdfs:label "VA dose 12a" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VADose13
:VADose13 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1600 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "1600 mg" ;
          rdfs:label "VA dose 13a" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VADose14
:VADose14 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "“high doses” of both drugs" ;
          rdfs:label "VA dose 14" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VADose17
:VADose17 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1000 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "1000 mg" ;
          rdfs:label "VA dose 17" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VADose18
:VADose18 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 2500 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "false" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "2500 mg" ;
          rdfs:label "VA dose 18" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VADose19
:VADose19 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 500 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "500 mg" ;
          rdfs:label "VA dose 19" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VADose2
:VADose2 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 600 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "600 mg" ;
         rdfs:label "VA dose 2" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VADose20
:VADose20 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1.5 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "1.5 mg" ;
          rdfs:label "VA dose 20" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VADose3
:VADose3 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 250 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "250 mg" ;
         rdfs:label "VA dose 3" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VADose4
:VADose4 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1000 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "false"^^xsd:boolean ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "1000 mg" ;
         rdfs:label "VA dose 4" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VADose5
:VADose5 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1000 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "1000 mg" ;
         rdfs:label "VA dose 5" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VADose6
:VADose6 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 300 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "300 mg" ;
         rdfs:label "VA dose 6" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VADose7
:VADose7 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 150 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "150 mg" ;
         rdfs:label "VA dose 7a" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VADose8
:VADose8 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1500 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "true" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "1500 mg" ;
         rdfs:label "VA dose 8" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VADose9
:VADose9 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 300 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "300 mg" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_partial_dechallenge_process> "true"^^xsd:boolean ;
         rdfs:label "VA dose 9" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_dose_12b
:VA_dose_12b rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1500 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "1500 mg" ;
             rdfs:label "VA dose 12b" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_dose_13b
:VA_dose_13b rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 2400 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "2400 mg" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_partial_dechallenge_process> "true"^^xsd:boolean ;
             rdfs:label "VA dose 13b" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_dose_7b
:VA_dose_7b rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :OneDayIntervalBetweenAdministrations ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg"^^xsd:string ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 300 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_process> "false"^^xsd:boolean ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "300 mg" ;
            rdfs:label "VA dose 7b" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_usage_for_Report1
:VA_usage_for_Report1 rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :VADose1 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
                      rdfs:label "VA usage for report 1" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_usage_for_Report10
:VA_usage_for_Report10 rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :VADose10 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
                       rdfs:label "VA usage for report 10" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_usage_for_Report11
:VA_usage_for_Report11 rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :VADose11 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
                       rdfs:label "VA usage for report 11" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_usage_for_Report12
:VA_usage_for_Report12 rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :VADose12 ,
                                                                                        :VA_dose_12b ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
                       rdfs:label "VA usage for report 12" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_usage_for_Report13
:VA_usage_for_Report13 rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :VADose13 ,
                                                                                        :VA_dose_13b ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
                       rdfs:label "VA usage for report 13" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_usage_for_Report14
:VA_usage_for_Report14 rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :VADose14 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
                       rdfs:label "VA usage for report 14" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_usage_for_Report17
:VA_usage_for_Report17 rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :VADose17 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
                       rdfs:label "VA usage for report 17" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_usage_for_Report18
:VA_usage_for_Report18 rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :VADose18 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
                       rdfs:label "VA usage for report 18" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_usage_for_Report19
:VA_usage_for_Report19 rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :VADose19 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
                       rdfs:label "VA usage for report 19" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_usage_for_Report2
:VA_usage_for_Report2 rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :VADose2 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
                      rdfs:label "VA usage for report 2" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_usage_for_Report20
:VA_usage_for_Report20 rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :VADose20 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
                       rdfs:label "VA usage for report 20" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_usage_for_Report3
:VA_usage_for_Report3 rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :VADose3 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
                      rdfs:label "VA usage for report 3" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_usage_for_Report4
:VA_usage_for_Report4 rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :VADose4 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
                      rdfs:label "VA usage for report 4" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_usage_for_Report5
:VA_usage_for_Report5 rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :VADose5 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
                      rdfs:label "VA usage for report 5" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_usage_for_Report6
:VA_usage_for_Report6 rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :VADose6 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
                      rdfs:label "VA usage for report 6" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_usage_for_Report7
:VA_usage_for_Report7 rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :VADose7 ,
                                                                                       :VA_dose_7b ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
                      rdfs:label "VA usage for report 7" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_usage_for_Report8
:VA_usage_for_Report8 rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :VADose8 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
                      rdfs:label "VA usage for report 8" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#VA_usage_for_Report9
:VA_usage_for_Report9 rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :VADose9 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :valproicAcid ;
                      rdfs:label "VA usage for report 9" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Valproic_acid
:Valproic_acid rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Mechanism> ;
               mp:references :Ref.1 ,
                             :Ref.2 ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Valproic acid is an antiepileptic, thought to increase gamma  aminobutyric acid concentrations in the brain." ;
               rdfs:label "Valproic acid mechanism" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#acetylsalicylicAcid
:acetylsalicylicAcid rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AC06" ,
                                                                                  "N02BA01 " ;
                     rdfs:label "acetylsalicylic acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#acidosisMetabolic
:acidosisMetabolic rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E87.2" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10027417 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Metabolic acidosis" ;
                   rdfs:label "acidosis metabolic" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#affectLability
:affectLability rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R45.86" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10054196 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Affect lability" ;
                rdfs:label "affect lability" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#against
:against rdf:type owl:NamedIndividual ,
                  <http://purl.obolibrary.org/obo/OAE_0001182> ;
         mp:references :Ref.21 ,
                       :Ref.22 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "For rhabdomyolysis and increases in blood CPK, the  time to onset is consistent with a drug induced  effect, yet the reactions per se could be explained by concomitant diseases, co-reported terms or  co-administered medicines. The musculoskeletal subgroup contributes with  4 males and 1 female to the uneven sex ratio  in the case series (13 males and 7 females).  Fat-to-muscle ratio differences between sexes  can account for rhabdomyolysis. Other  alternative explanations include: potentially  undiagnosed glycolysis, glycogenolysis, and  pentose phosphate pathways enzymatic  polymorphism, mitochondrial toxicity and  calcium homeostasis dysregulation. 21 Additionally, rhabdomyolysis is part of the  neuroleptic malignant syndrome (NMS) clinical  presentation, which is known to be more  frequent in men" ;
         rdfs:label "Confounders and other theories against causality" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#alfuzosin
:alfuzosin rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "G04CA01 " ;
           rdfs:label "alfuzosin" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#alteredStateOfConsciousness
:alteredStateOfConsciousness rdf:type owl:NamedIndividual ,
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R40.4" ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10001854 ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Altered state of consciousness" ;
                             rdfs:label "altered state of consciousness" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#amlodipine
:amlodipine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C08CA01" ;
            rdfs:label "amlodipine" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#anticonvulsantDrugLevelAboveTherapeutic
:anticonvulsantDrugLevelAboveTherapeutic rdf:type owl:NamedIndividual ,
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "Z51.81" ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10054807 ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Anticonvulsant drug level above therapeutic" ;
                                         rdfs:label "anticonvulsant drug level above therapeutic" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#aripiprazole
:aripiprazole rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05AX12" ;
              rdfs:label "aripiprazole" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#bloodCholesterolIncreased
:bloodCholesterolIncreased rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E78.00" ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10005425 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Blood cholesterol increased" ;
                           rdfs:label "blood cholesterol increased" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#bloodCreatinePhosphokinaseIncreased
:bloodCreatinePhosphokinaseIncreased rdf:type owl:NamedIndividual ,
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R74.8" ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10005470 ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Blood creatine phosphokinase increased" ;
                                     rdfs:label "blood creatine phosphokinase increased" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#bloodThyroidStimulatingHormoneDecreased
:bloodThyroidStimulatingHormoneDecreased rdf:type owl:NamedIndividual ,
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R94.6" ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10005832 ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Blood thyroid stimulating hormone decreased" ;
                                         rdfs:label "blood thyroid stimulating hormone decreased" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#bodyTemperatureIncreased
:bodyTemperatureIncreased rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R50.9" ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10005911 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Body temperature increased" ;
                          rdfs:label "body temperature increased" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#bronchopneumonia
:bronchopneumonia rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J18.0" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10035664 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pneumonia" ;
                  rdfs:label "bronchopneumonia" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#ceftriaxone
:ceftriaxone rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01DD04 " ;
             rdfs:label "ceftriaxone" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#clopidogrel
:clopidogrel rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AC04" ;
             rdfs:label "clopidogrel" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#cognitiveDeterioration
:cognitiveDeterioration rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G31.84" ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10057668 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Cognitive disorder" ;
                        rdfs:label "cognitive deterioration" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#coma
:coma rdf:type owl:NamedIndividual ,
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R40" ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10010071 ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Coma" ;
      rdfs:label "coma" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#concentrationImpaired
:concentrationImpaired rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R41.840" ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10013496 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Disturbance in attention" ;
                       rdfs:label "concentration impaired" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#conciousnessClouding
:conciousnessClouding rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R41.0" ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10010767 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Consciousness clouding" ;
                      rdfs:label "conciousness clouding" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#conclusion
:conclusion rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Conclusion> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The potential for quetiapine-valproic acid interactions has been extensively described in the literature, with at least six case reports published in journals. The assessed case series features musculoskeletal and psychiatric events that occurred after dose increases of quetiapine, or where the reporter suspected a pharmacokinetic interaction. Bearing reported confounders in mind, such as NMS, or individual predisposing factors, current information could still be considered for updating. In particularly, the co-administration of quetiapine and valproic acid is regarded as well tolerated, yet 15 out of 20 cases were serious. While psychiatrists and clinical pharmacologists might be aware of the events described here, general practitioners might not be, stressing the relevance of strengthening the safety understanding and available documentation on the two medicines." ;
            rdfs:label "conclusion" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#confusion
:confusion rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "F44.8" ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10010305 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Confusional state" ;
           rdfs:label "confusion" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#consciousnessDecreased
:consciousnessDecreased rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R41.82" ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10012373 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Depressed level of consciousness" ;
                        rdfs:label "consciousness decreased" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#convulsions
:convulsions rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R56.8" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10039906 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Seizure" ;
             rdfs:label "convulsions" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#creatineKinaseMbIncreased
:creatineKinaseMbIncreased rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R74.8" ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10005474 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Blood creatine phosphokinase MB increased" ;
                           rdfs:label "creatine kinase mb increased" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#dehydration
:dehydration rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E86.0" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10012174 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Dehydration" ;
             rdfs:label "dehydration" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#delorazepam
:delorazepam rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05BA06 " ;
             rdfs:label "delorazepam" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#depressedLevelOfConsciousness
:depressedLevelOfConsciousness rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R41.82" ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10012373 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Depressed level of consciousness" ;
                               rdfs:label "depressed level of consciousness" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#diabetesInsipidus
:diabetesInsipidus rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E23.2" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10012599 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Diabetes insipidus" ;
                   rdfs:label "diabetes insipidus" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#diabetesMellitus
:diabetesMellitus rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E08-E13" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10012601 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Diabetes mellitus" ;
                  rdfs:label "diabetes mellitus" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#diabeticKetoacidosis
:diabeticKetoacidosis rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E10.10" ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10012671 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Diabetic ketoacidosis" ;
                      rdfs:label "diabetic ketoacidosis" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#disorientation
:disorientation rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R41.1" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10013395 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Disorientation" ;
                rdfs:label "disorientation" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#dizziness
:dizziness rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R42" ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10013573 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Dizziness" ;
           rdfs:label "dizziness" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#drowsiness
:drowsiness rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R40" ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10041349 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Somnolence" ;
            rdfs:label "drowsiness" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#drugClearanceDecreased
:drugClearanceDecreased rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R82.5" ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10049463 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Drug clearance decreased" ;
                        rdfs:label "drug clearance decreased" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#drugInteraction
:drugInteraction rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "T88.7XXA" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10013710 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Drug interaction" ;
                 rdfs:label "drug interaction" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#dysarthria
:dysarthria rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R47.1" ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10013887 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Dysarthria" ;
            rdfs:label "dysarthria" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#extrapyramidalDisorder
:extrapyramidalDisorder rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G25.9" ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10015832 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Extrapyramidal disorder" ;
                        rdfs:label "extrapyramidal disorder" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#fever
:fever rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R50.9" ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10037660 ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pyrexia" ;
       rdfs:label "fever" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#finasteride
:finasteride rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "G04CB01 " ;
             rdfs:label "finasteride" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#flurazepam
:flurazepam rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05CD01 " ;
            rdfs:label "flurazepam" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#fluvoxamine
:fluvoxamine rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06AB08" ;
             rdfs:label "fluvoxamine" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#furosemide
:furosemide rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03CA01" ;
            rdfs:label "furosemide" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#gaitDisturbance
:gaitDisturbance rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R26" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10017577 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Gait disturbance" ;
                 rdfs:label "gait disturbance" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#hemiparesis
:hemiparesis rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G81" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10019465 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hemiparesis" ;
             rdfs:label "hemiparesis" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#heparin
:heparin rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AB01" ;
         rdfs:label "heparin" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#hepaticEnzymesIncreased
:hepaticEnzymesIncreased rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R94.5" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10060795 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hepatic enzyme increased" ;
                         rdfs:label "hepatic enzymes increased" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#hyperammonemia
:hyperammonemia rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E72.20" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10020575 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hyperammonaemia" ;
                rdfs:label "hyperammonemia" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#hyperammonemicComa
:hyperammonemicComa rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E72.20" ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10073510 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hyperammonemic crisis" ;
                    rdfs:label "hyperammonemic coma" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#hyperammonemicEncephalopathy
:hyperammonemicEncephalopathy rdf:type owl:NamedIndividual ,
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E72.20" ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10067327 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hyperammonaemic encephalopathy" ;
                              rdfs:label "hyperammonemic encephalopathy" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#hypercapnia
:hypercapnia rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R06.89" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10020591 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hypercapnia" ;
             rdfs:label "hypercapnia" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#hyperglycaemia
:hyperglycaemia rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R73.9" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10020635 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hyperglycaemia" ;
                rdfs:label "hyperglycaemia" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#hypernatraemia
:hypernatraemia rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E87.0" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10020679 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hypernatraemia" ;
                rdfs:label "hypernatraemia" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#hyperosmolarState
:hyperosmolarState rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> " E11.00" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10020697 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hyperosmolar state" ;
                   rdfs:label "hyperosmolar state" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#hypertriglyceridemia
:hypertriglyceridemia rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> " E78.1" ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10020869 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hypertriglyceridaemia" ;
                      rdfs:label "hypertriglyceridemia" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#hypotension
:hypotension rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I95.9" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10021097 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hypotension" ;
             rdfs:label "hypotension" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#hypoxia
:hypoxia rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R09.02" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10021143 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hypoxia" ;
         rdfs:label "hypoxia" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#inappropriateScheduleOfDrugAdministration
:inappropriateScheduleOfDrugAdministration rdf:type owl:NamedIndividual ,
                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10081572 ;
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Inappropriate schedule of product administration" ;
                                           rdfs:label "inappropriate schedule of drug administration" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#indapamide
:indapamide rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03BA11" ;
            rdfs:label "indapamide" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#introduction
:introduction rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Introduction> ;
              mp:references :Ref.1 ,
                            :Ref.2 ,
                            :Ref.3 ,
                            :Ref.4 ,
                            :Ref.5 ,
                            :Ref.6 ,
                            :Ref.7 ,
                            :Ref.8 ,
                            :Ref.9 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Quetiapine is an atypical antipsychotic, with  antagonistic activity for serotonin 5-HT 1A /5-HT 2 ,  dopamine D 1 /D 2 , histamine H 1 and noradrenaline α 1 and α 2 receptors. It is indicated for schizophrenia,  bipolar disorder I, and as add-on treatment for  major depressive disorder. Valproic acid is an  antiepileptic, thought to increase gamma  aminobutyric acid concentrations in the brain. 1,2 In the United States (US) and Europe, quetiapine  and valproic acid together are licensed for the  treatment of acute moderate to severe manic  episodes in bipolar disorder and as  maintenance treatment of bipolar disorder  (prevention of a manic, mixed or depressive  episode) in adults. 1,2  Limited evidence shows  that co-administration of quetiapine and  valproic acid in bipolar disorder is more  effective than use on their own, both for acute  symptoms and maintenance. 3-6  Relatively high  co-prescription as opposed to monotherapy  emphasizes the need for better understanding  of the efficacy of antipsychotics, including  quetiapine, in conjunction with lithium,  lamotrigine or valproic acid, contrasting. 7 Recommended doses of quetiapine in adjunct  to valproic acid, for both acute and  maintenance bipolar disorder treatment, are  400-800 mg per day. Immediate release  quetiapine is initiated at 100 mg per day in  manic episodes and may be increased up to  800 mg/day over six days, with increments  no higher than 200 mg/day. For extended  release: 300 mg/day for the first two days,  with 400-800 mg/day by day three. Valproic  acid doses in mania are mostly documented  as monotherapy at 600-750 mg/day. The  dose should be increased by 200 mg/day  every three days, up to a total of 2500  mg/day in uncontrolled mania. 8,9 The polymorphic nature of psychotic disorders  poses a challenge to standard posology  recommendations or specific combination  treatments. Off-label use is common in  psychiatry, to explore treatments to which  each patient responds most  favourably." ;
              rdfs:label "introduction" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#known_interaction
:known_interaction rdf:type owl:NamedIndividual ,
                            <http://purl.obolibrary.org/obo/OAE_0001197> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug_drug_interaction> :quetiapine_and_valproic_acid_interaction ;
                   mp:references :Ref.20 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Quetiapine and valproic acid are known to interact as two central nervous system (CNS) depressant agents. The interaction is not thought to be clinically significant and is regarded as “well tolerated”, however, therapeutic drug monitoring has been recommended.20" ;
                   rdfs:label "known interaction" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#levothyroxine
:levothyroxine rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "H03AA01" ;
               rdfs:label "levothyroxine" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#lipidsIncreased
:lipidsIncreased rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E78.5" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10024592 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Lipids increased" ;
                 rdfs:label "lipids increased" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#lithium
:lithium rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05AN01" ;
         rdfs:label "lithium" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#lorazepam
:lorazepam rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05BA06" ;
           rdfs:label "lorazepam" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#majorDepressiveDisorder
:majorDepressiveDisorder rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "F32" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10057840 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Major depression" ;
                         rdfs:label "major depressive disorder" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#malaise
:malaise rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R53.8 " ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10025482 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Malaise" ;
         rdfs:label "malaise" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#memoryDeficit
:memoryDeficit rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R41.3" ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10027175 ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Memory impairment" ;
               rdfs:label "memory deficit" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#metronidazole
:metronidazole rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A01AB17" ;
               rdfs:label "metronidazole" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#musclePain
:musclePain rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "M79.1" ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10028411 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Myalgia" ;
            rdfs:label "muscle pain" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#muscleRigidity
:muscleRigidity rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "M62.9" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10028330 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Muscle rigidity" ;
                rdfs:label "muscle rigidity" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#muscleSpasticity
:muscleSpasticity rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "M62.838" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10028335 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Muscle spasticity" ;
                  rdfs:label "muscle spasticity" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#muscleWeakness
:muscleWeakness rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "M62.8" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10028372 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Muscular weakness" ;
                rdfs:label "muscle weakness" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#musculoskeletalStiffness
:musculoskeletalStiffness rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "M25.60" ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10052904 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Musculoskeletal stiffness" ;
                          rdfs:label "musculoskeletal stiffness" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#myoglobinBloodIncreased
:myoglobinBloodIncreased rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R79.89" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10028625 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Myoglobin blood increased" ;
                         rdfs:label "myoglobin blood increased" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#myopathy
:myopathy rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G72.9" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10028641 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Myopathy" ;
          rdfs:label "myopathy" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#nausea
:nausea rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R11" ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10028813 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Nausea" ;
        rdfs:label "nausea" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#neckStiffness
:neckStiffness rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "M25.60" ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10052904 ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Musculoskeletal stiffness" ;
               rdfs:label "neck stiffness" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#neurolepticMalignantSyndrome
:neurolepticMalignantSyndrome rdf:type owl:NamedIndividual ,
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G21.0" ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10029282 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Neuroleptic malignant syndrome" ;
                              rdfs:label "neuroleptic malignant syndrome" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#nifedipine
:nifedipine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C08CA05" ;
            rdfs:label "nifedipine" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#overdose
:overdose rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "T50.901A" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10033295 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Overdose" ;
          rdfs:label "overdose" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#oxcarbazepine
:oxcarbazepine rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N03AF02" ;
               rdfs:label "oxcarbazepine" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#pain
:pain rdf:type owl:NamedIndividual ,
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G89.1" ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10033371 ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pain" ;
      rdfs:label "pain" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#paliperidone
:paliperidone rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05AX13 " ;
              rdfs:label "paliperidone" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#pantoprazole
:pantoprazole rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BC02" ;
              rdfs:label "pantoprazole" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#paranoidSchizophrenia
:paranoidSchizophrenia rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "F20.0" ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10039626 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Schizophrenia" ;
                       rdfs:label "paranoid  schizophrenia" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#parkinsonism
:parkinsonism rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G20" ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10034010 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Parkinsonism" ;
              rdfs:label "parkinsonism" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#paroxetine
:paroxetine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06AB05" ;
            rdfs:label "paroxetine" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#perazine
:perazine rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05AB10 " ;
          rdfs:label "perazine" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#physicalAssault
:physicalAssault rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "Y04" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10034983 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Physical assault" ;
                 rdfs:label "physical assault" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#pipamperone
:pipamperone rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05AD05" ;
             rdfs:label "pipamperone" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#pneumonia
:pneumonia rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J15.8" ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10035664 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pneumonia" ;
           rdfs:label "pneumonia" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#posttraumaticStressDisorder
:posttraumaticStressDisorder rdf:type owl:NamedIndividual ,
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "F43.1" ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10036316 ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Post-traumatic stress disorder" ;
                             rdfs:label "posttraumatic stress disorder" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#prescribedOverdose
:prescribedOverdose rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10051076 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Prescribed overdose" ;
                    rdfs:label "prescribed overdose" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#pvSignal
:pvSignal rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Signal> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> :Discussion ,
                                                                                      :Reports_in_VigiBase ,
                                                                                      :conclusion ,
                                                                                      :introduction ,
                                                                                      :summary ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_supported_by_individual_case_report> :Report1 ,
                                                                                                 :Report10 ,
                                                                                                 :Report11 ,
                                                                                                 :Report12 ,
                                                                                                 :Report13 ,
                                                                                                 :Report14 ,
                                                                                                 :Report15 ,
                                                                                                 :Report16 ,
                                                                                                 :Report17 ,
                                                                                                 :Report18 ,
                                                                                                 :Report19 ,
                                                                                                 :Report2 ,
                                                                                                 :Report20 ,
                                                                                                 :Report3 ,
                                                                                                 :Report4 ,
                                                                                                 :Report5 ,
                                                                                                 :Report6 ,
                                                                                                 :Report7 ,
                                                                                                 :Report8 ,
                                                                                                 :Report9 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_supported_by_statistical_entity> :OverallReportsInVigibaseForQAndVAco-reportedAsSuspectedOrInteracting ,
                                                                                             :ReportsFocusingOndrug-drugInteractionsForQAndVA ,
                                                                                             :ReportsFromAustralia ,
                                                                                             :ReportsFromCanada ,
                                                                                             :ReportsFromDenmark ,
                                                                                             :ReportsFromGermany ,
                                                                                             :ReportsFromItaly ,
                                                                                             :ReportsFromSouthKorea ,
                                                                                             :ReportsFromSpain ,
                                                                                             :ReportsFromSwitzerland ,
                                                                                             :ReportsFromTurkey ,
                                                                                             :ReportsFromUSA ,
                                                                                             :Reports_remaining_for_MedDRA_PTs ,
                                                                                             :Reports_with_Batten_disease_as_indication ,
                                                                                             :Reports_with_Depressed_level_of_conciousness_as_adverse_event_at_PT_level ,
                                                                                             :Reports_with_Disorientation_as_adverse_event_at_PT_level ,
                                                                                             :Reports_with_Rhabdomyolysis_as_adverse_event_at_PT_level ,
                                                                                             :Reports_with_bipolar_disorder_as_indication ,
                                                                                             :Reports_with_dipression_as_indication ,
                                                                                             :Reports_with_patient_restraint_as_indication ,
                                                                                             :Reports_with_posttraumatic_stress_disorder_as_indication ,
                                                                                             :Reports_with_schizoaffective_disorder_as_indication ,
                                                                                             :Reports_with_schizophrenia_as_indication ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_''Blood_creatine_phosphokinase_increased''_as_adverse_event_at_PT_level> ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_''Coma''_as_adverse_event_at_PT_level> ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_psychotic_disorder/psychosis_as_indication> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :bloodCreatinePhosphokinaseIncreased ,
                                                                                   :coma ,
                                                                                   :creatineKinaseMbIncreased ,
                                                                                   :depressedLevelOfConsciousness ,
                                                                                   :disorientation ,
                                                                                   :rhabdomyolysis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :DosageForExtendedReleaseQForManicEpisodes ,
                                                                           :DosageForImmediateReleaseQForManicEpisodes ,
                                                                           :DosageForReportsWithMusculoskeletalReportedAdverseEventsPTs ,
                                                                           :DosageForReportsWithNeuropsychiatricReportedAdverseEventsPTs ,
                                                                           :DosageForVAInMania ,
                                                                           :Dosage_info ,
                                                                           :RecommendedDoseOfQInAdjunctWithVA ,
                                                                           :Reports_with_Depressed_level_of_conciousness_as_adverse_event_at_PT_level ,
                                                                           :Reports_with_Disorientation_as_adverse_event_at_PT_level ,
                                                                           :Reports_with_Rhabdomyolysis_as_adverse_event_at_PT_level ,
                                                                           :Reports_with_bipolar_disorder_as_indication ,
                                                                           :Reports_with_dipression_as_indication ,
                                                                           :Reports_with_patient_restraint_as_indication ,
                                                                           :Reports_with_posttraumatic_stress_disorder_as_indication ,
                                                                           :Reports_with_schizoaffective_disorder_as_indication ,
                                                                           :Reports_with_schizophrenia_as_indication ,
                                                                           <http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_''Blood_creatine_phosphokinase_increased''_as_adverse_event_at_PT_level> ,
                                                                           <http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_''Coma''_as_adverse_event_at_PT_level> ,
                                                                           <http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_psychotic_disorder/psychosis_as_indication> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ,
                                                                         :valproicAcid ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug_drug_interaction> :quetiapine_and_valproic_acid_interaction ;
          mp:supportedByData :AstraZeneca_sponsored_study ,
                             :EU_SmPC_for_quetiapine ,
                             :EU_SmPC_for_valproic_acid ,
                             :Smaller_study ,
                             :against ,
                             :known_interaction ,
                             :smoking ,
                             <http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Stockley’s_Drug_Interactions> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#initially_identified_on> "01/03/2018" ;
          rdfs:label "pv signal" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#pyrexia
:pyrexia rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R50.9" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10037660 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pyrexia" ;
         rdfs:label "pyrexia" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#quetiapine
:quetiapine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :BipolarDisorder ,
                                                                                        :Schizophrenia ,
                                                                                        :majorDepressiveDisorder ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_mechanism> :Quetiapine_Mechanism ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05AH04 " ;
            rdfs:label "quetiapine" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#quetiapine_and_valproic_acid_interaction
:quetiapine_and_valproic_acid_interaction rdf:type owl:NamedIndividual ,
                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Drug-Drug_interaction> ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interacting_drug> :quetiapine ,
                                                                                                                     :valproicAcid ;
                                          rdfs:label "quetiapine and valproic acid interaction" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#ramipril
:ramipril rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C09AA05" ;
          rdfs:label "ramipril" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#renalFailureAcute
:renalFailureAcute rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "N17.9" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10069339 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Acute kidney injury" ;
                   rdfs:label "renal failure acute" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#restlessness
:restlessness rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R45.1" ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10038743 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Restlessness" ;
              rdfs:label "restlessness" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#rhabdomyolysis
:rhabdomyolysis rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "M62.82" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10039020 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Rhabdomyolysis" ;
                rdfs:label "rhabdomyolysis" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#rigors
:rigors rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> " R68.83" ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10039177 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Rigors" ;
        rdfs:label "rigors" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#sertraline
:sertraline rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06AB06" ;
            rdfs:label "sertraline" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#smoking
:smoking rdf:type owl:NamedIndividual ,
                  <http://purl.obolibrary.org/obo/OAE_0001182> ;
         mp:references :Ref.24 ,
                       :Ref.25 ,
                       :Ref.26 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """In addition to polytherapy-induced interactions, 
smoking, alcohol, and drug abuse are prevalent in 
patients affected by psychotic disorders.24
Quetiapine pharmacokinetics do not seem to be 
altered by smoking. Nicotine however, is 
metabolized by CYP2A6, the same cytochrome 
which hydroxylates valproic acid.25,26 These 
considerations are applicable to case 7, a smoker. 
Smoker status, alcohol or substance abuse could 
have been unreported in the rest of the case series.""" ;
         rdfs:label "smoking" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#somnolence
:somnolence rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R40.0" ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10041349 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Somnolence" ;
            rdfs:label "somnolence" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#speechDisorder
:speechDisorder rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "F80.9" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10041466 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Speech disorder" ;
                rdfs:label "speech disorder" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#summary
:summary rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Summary> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The co-administration of quetiapine and valproic  acid is a relatively unexplored option for the acute  and maintenance treatment of bipolar disorder.  According to the European Union Summary of  Product Characteristics, the two drugs are known to interact but the co-treatment is “well tolerated”.  Despite the limited clinical significance of the  interaction, some have advised therapeutic drug  monitoring. In December 2016, VigiBase, the WHO  global database of individual case safety reports,  held over 1500 reports of quetiapine and valproic  acid as co-suspect or interacting. Five MedDRA  preferred terms: blood creatine phosphokinase  increased, coma, depressed level of consciousness,  disorientation and rhabdomyolysis were selected  through shrinkage odds ratios. The resulting series of 20 cases was assessed: at least six cases had  been reported in the literature, there were more  male than female rhabdomyolysis patients (4:1),  and quetiapine raised plasma concentrations hinted  at a valproic acid-mediated pharmacokinetic  interaction. Most cases (15/20) were reported as  serious, and therefore, despite confounding by  neuroleptic malignant syndrome and the potential  for genetic polymorphisms, the evidence presented  may justify an update to the current safety  understanding of the two medicines." ;
         rdfs:label "summary" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#temporalDisorientation
:temporalDisorientation rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R41.0" ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10013395 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Disorientation" ;
                        rdfs:label "temporal disorientation" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#thinkingAbnormal
:thinkingAbnormal rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R41.0" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10043431 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Thinking abnormal" ;
                  rdfs:label "thinking abnormal" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#torasemide
:torasemide rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03CA04" ;
            rdfs:label "torasemide" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#treatmentNoncompliance
:treatmentNoncompliance rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "Z91.19" ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10049414 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Treatment noncompliance" ;
                        rdfs:label "treatment noncompliance" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#tremor
:tremor rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R25.1" ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10044565 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Tremor" ;
        rdfs:label "tremor" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#valproicAcid
:valproicAcid rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_mechanism> :Valproic_acid ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N03AG01" ;
              rdfs:label "valproic acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#venlafaxine
:venlafaxine rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06AX16" ;
             rdfs:label "venlafaxine" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#weightIncreased
:weightIncreased rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R63.5" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10047899 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Weight increased" ;
                 rdfs:label "weight increased" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Quetiapine_and_valproic_acid_interactions:_signal_strengthening
:Quetiapine_and_valproic_acid_interactions:_signal_strengthening rdf:type owl:NamedIndividual ,
                                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Pharmacovigilance_Signal_Report> ;
                                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_author> :Daniele_Sartori ,
                                                                                                                                  :Prof._Alfonso_Carvajal ;
                                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_signal> :pvSignal ;
                                                                 mp:publishedBy :Uppsala_Monitoring_Centre ;
                                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "01/03/2018"^^xsd:date ;
                                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_overall_conclusion> "causal association probable" ;
                                                                 rdfs:label "Quetiapine and valproic acid interactions: signal strengthening" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_''Blood_creatine_phosphokinase_increased''_as_adverse_event_at_PT_level
<http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_''Blood_creatine_phosphokinase_increased''_as_adverse_event_at_PT_level> rdf:type owl:NamedIndividual ,
                                                                                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                                                                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_unconfirmed_adverse_effect> :bloodCreatinePhosphokinaseIncreased ;
                                                                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 5 ;
                                                                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                                                                               rdfs:label "Reports with Blood creatine phosphokinase increased as adverse event at PT level" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_''Coma''_as_adverse_event_at_PT_level
<http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_''Coma''_as_adverse_event_at_PT_level> rdf:type owl:NamedIndividual ,
                                                                                                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                                                                                                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_unconfirmed_adverse_effect> :coma ;
                                                                                                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 5 ;
                                                                                                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                                             rdfs:label "Reports with Coma as adverse event at PT level" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_psychotic_disorder/psychosis_as_indication
<http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Reports_with_psychotic_disorder/psychosis_as_indication> rdf:type owl:NamedIndividual ,
                                                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> <http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#psychoticdisorder/psychosis> ;
                                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_remaining_for_MedDRA_PTs ;
                                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                                                  rdfs:label "Reports with psychotic didorder/psychosis as indication" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Stockley’s_Drug_Interactions
<http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#Stockley’s_Drug_Interactions> rdf:type owl:NamedIndividual ,
                                                                                                                <http://purl.obolibrary.org/obo/OAE_0001182> ;
                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :quetiapine ,
                                                                                                                                                                      :valproicAcid ;
                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug_drug_interaction> :quetiapine_and_valproic_acid_interaction ;
                                                                                                       mp:references :Ref.12 ;
                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Stockley’s Drug Interactions describe the evidence on a pharmacokinetic interaction between quetiapine and valproic acid as “limited”, adding that the two do not appear to alter each other’s exposure. Based on the evidence considered, dose adjustments are not deemed necessary in concurrent use.12" ;
                                                                                                       rdfs:label "Stockley’s Drug Interactions" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#hydrochlorothiazide/lisinopril
<http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#hydrochlorothiazide/lisinopril> rdf:type owl:NamedIndividual ,
                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C09BA03 " ;
                                                                                                         rdfs:label "hydrochlorothiazide / lisinopril" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#hydrochlorothiazide/valsartan
<http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#hydrochlorothiazide/valsartan> rdf:type owl:NamedIndividual ,
                                                                                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C09DA03" ;
                                                                                                        rdfs:label "hydrochlorothiazide / valsartan" .


###  http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#psychoticdisorder/psychosis
<http://purl.org/OpenPVSignal/Signals/2018_2_quetiapine_valproicAcid.owl#psychoticdisorder/psychosis> rdf:type owl:NamedIndividual ,
                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                                                                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "F23" ;
                                                                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10061920 ;
                                                                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Psychotic disorder" ;
                                                                                                      rdfs:label "psychotic  disorder/psychosis" .


###  Generated by the OWL API (version 4.5.9.2019-02-01T07:24:44Z) https://github.com/owlcs/owlapi
